DexCom Inc logo

DexCom Inc (DXCM)

Market Open
1 May, 16:18
NASDAQ (NGS) NASDAQ (NGS)
$
69. 88
-1.5
-2.1%
$
30.57B Market Cap
134.71 P/E Ratio
0% Div Yield
69,708 Volume
1.43 Eps
$ 71.38
Previous Close
Day Range
69.72 71.64
Year Range
57.52 132.26

Summary

DXCM trading today lower at $69.88, a decrease of 2.1% from yesterday's close, completing a monthly increase of 2.99% or $2.03. Over the past 12 months, DXCM stock lost -10.26%.
DXCM is not paying dividends to its shareholders.
The last earnings report, released on Apr 23, 2025, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.02%, based on the last three reports.
DexCom Inc has completed 1 stock splits, with the recent split occurring on Jun 13, 2022.
The company's stock is traded on 11 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
Want to track DXCM and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

DXCM Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Gear Up for DexCom (DXCM) Q1 Earnings: Wall Street Estimates for Key Metrics

Gear Up for DexCom (DXCM) Q1 Earnings: Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for DexCom (DXCM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.

Zacks | 2 days ago
DXCM Q1 Earnings to Reflect U.S. Coverage Expansion & Stelo Impact?

DXCM Q1 Earnings to Reflect U.S. Coverage Expansion & Stelo Impact?

DexCom Q1 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo traction, driving momentum and market expansion in 2025.

Zacks | 2 days ago
Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders

Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders

SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws.

Globenewswire | 1 week ago

DexCom Inc Dividends

DXCM is not paying dividends to its shareholders.

DexCom Inc Earnings

23 Apr 2025 Date
-
Cons. EPS
-
EPS
6 Feb 2025 Date
0.52
Cons. EPS
0.45
EPS
24 Oct 2024 Date
0.44
Cons. EPS
0.45
EPS
25 Jul 2024 Date
0.39
Cons. EPS
0.43
EPS
5 Jun 2024 Date
0.27
Cons. EPS
0.32
EPS
DXCM is not paying dividends to its shareholders.
23 Apr 2025 Date
-
Cons. EPS
-
EPS
6 Feb 2025 Date
0.52
Cons. EPS
0.45
EPS
24 Oct 2024 Date
0.44
Cons. EPS
0.45
EPS
25 Jul 2024 Date
0.39
Cons. EPS
0.43
EPS
5 Jun 2024 Date
0.27
Cons. EPS
0.32
EPS

DexCom Inc (DXCM) FAQ

What is the stock price today?

The current price is $69.88.

On which exchange is it traded?

DexCom Inc is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is DXCM.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 30.57B.

Has DexCom Inc ever had a stock split?

DexCom Inc had 1 splits and the recent split was on Jun 13, 2022.

DexCom Inc Profile

Medical Devices Industry
Healthcare Sector
Mr. Kevin Ronald Sayer CEO
NASDAQ (NGS) Exchange
US2521311074 ISIN
Germany Country
- Employees
- Last Dividend
13 Jun 2022 Last Split
14 Apr 2005 IPO Date

Overview

DexCom, Inc. is an innovative medical device company with a strong focus on the design, development, and commercialization of continuous glucose monitoring (CGM) systems. Founded in 1999 and based in San Diego, California, DexCom has made significant strides in providing state-of-the-art diabetes management solutions. Their products cater to both individuals with diabetes and healthcare providers, offering advanced technology for continuous glucose tracking both in the United States and internationally. Through strategic collaborations, including agreements with Verily Life Sciences LLC and Verily Ireland Limited, DexCom continues to pioneer in the pursuit of enhancing diabetes care with the aim of developing new glucose monitoring products. The company's approach to directly market its innovations to endocrinologists, physicians, and diabetes educators underscores their commitment to integrating their systems into the healthcare community, thereby ensuring they meet the needs of their end-users effectively.

Products and Services

  • Dexcom G6 and Dexcom G7: These integrated CGM systems are designed for comprehensive diabetes management. They allow users to monitor their glucose levels continuously without the need for routine finger pricks. By providing real-time glucose data, the Dexcom G6 and G7 help individuals with diabetes maintain better control over their condition.
  • Dexcom Share: This service facilitates remote monitoring, enabling users to share their glucose data with up to five followers. Dexcom Share is especially beneficial for caregivers who need to monitor the glucose levels of loved ones, adding a layer of safety and peace of mind for both the users and their families.
  • Dexcom Real-Time API: With this offering, DexCom opens the door for authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices. This connectivity enhances the ecosystem of diabetes management tools, allowing for more personalized and efficient care plans.
  • Dexcom ONE: Aimed at simplifying diabetes management, Dexcom ONE is designed to replace fingerstick blood glucose testing entirely for treatment decisions. This product targets a broader audience, making CGM technology more accessible to those who may benefit from continuous glucose insights without the traditional hassles of blood glucose testing.
  • Dexcom Stelo: Currently under FDA review, Dexcom Stelo is geared toward individuals with type 2 diabetes. This addition to DexCom's product line underscores the company's continuous effort to cater to the diverse needs of the diabetes community, aiming to simplify and improve the quality of diabetes care across the board.

Contact Information

Address: 6340 Sequence Drive
Phone: 858 200 0200